Once-weekly ALTUVIIIO® approved in Japan as a new class of factor VIII therapy for hemophilia A Post author: Post published:September 25, 2023 Post category:uncategorized The Japanese Ministry of Health, Labor, and Welfare (MHLW) has granted marketing authorization for ALTUVIIIO. You Might Also Like Scientists say NIH officials told them to scrub mRNA references on grants March 17, 2025 High-dose vitamin D3 cannot be recommended as treatment for metastatic colon cancer September 16, 2024 Icaritin softgel capsules offer new hope for hepatocellular carcinoma patients February 17, 2025
High-dose vitamin D3 cannot be recommended as treatment for metastatic colon cancer September 16, 2024